SEC Form 4 · accession 0001333277-18-000039
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Menold
Officer — Vice President, Finance
Period of report
Aug 29, 2018
Accepted (ET)
Aug 31, 2018 · 7:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 29, 2018 | M | 5,000 | $5.00 | A | 5,000 | D | |
| Common Stock | Aug 29, 2018 | S | 5,000 | $13.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $5.00 | Aug 29, 2018 | M | 5,000 | D | — | Jan 21, 2024 | Common Stock | 5,000 | 14,459 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2The option vested as to 1/4 of the shares on January 22, 2015 and 1/36 per month thereafter.